The novel second-generation IV/oral triterpenoid SCY-247 is efficacious in an experimental murine model of invasive candidiasis caused by Candida glabrata

SCY-247, a Novel Second-Generation IV/Oral Triterpenoid Antifungal, Demonstrates In vitro Activity Against Fungal Pathogens, Including Azole-Resistant Strains of Candida and Aspergillus

SCY-247, a novel second-generation IV/oral triterpenoid antifungal, is efficacious in the neutropenic mouse model of pulmonary mucormycosis

SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL: IN VITRO ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION IN VIVO

A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy

FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp

Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with Candida auris (CARES)

A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans Antimicrobial Agents and Chemotherapy

A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates Antimicrobial Agents and Chemotherapy

SCY-078 Displays Significant In Vitro Activity Against Multi Drug Resistant (MDR) Candida albicans and Candida glabrata Isolates